

## IVMB0231

---

### Product Information

**Product SKU:** IVMB0231

**Clone:** Hu107

**Target:** CD25

**Size:** 500 µg

**Isotype:** Human IgG1κ

---

### Additional Information

**Reactivity:** Human/Rhesus Monkey/Cynomolgus Monkey

**Host Species:** Human

**Antibody Type:** Biosimilar Recombinant Human Monoclonal Antibody

**Expression Host:** HEK-293 Cells

---

### Immunogen Information

**Background:** CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2R $\alpha$ . It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects.

**Endotoxin Level:** < 1.0 EU/mg as determined by the LAL method

**Applications:** B

**Synonyms:** IL-2-RA; IL2-RA; TAC antigen; p55; CD25

**Antigen Distribution:** IL-2R $\alpha$  is expressed on activated mature T and B lymphocytes, during early stages of thymocytes development, pre-B cells, and in activated CD4+ memory T-lymphocytes.

**Immunogen:** Human CD25

**Formulation:** This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium

or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

**Specificity:**

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Basiliximab. Basiliximab recognizes human CD25. This product is for research use only.

**Product Preparation:**

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

**Storage & Handling:**

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.